Analysis of CTLA-4 -318C/T Polymorphism in Thalassemia Patients Transfused at the Casablanca Children's Hospital (Morocco)

##plugins.themes.bootstrap3.article.main##

  •   Samira El Kababi

  •   Bouchra El Khalfi

  •   Khadija El Maani

  •   Abdelaziz Soukri

Abstract

Red blood cells (RBC) alloimmunization is a delayed adverse transfusion reaction in thalassemia patients. The mechanisms behind the inhibition or tolerance of red blood cells are still poorly understood. Cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) molecule is expressed on Treg -lymphocyte membrane and is an inhibitory molecule which plays the mediator role of peripheral tolerance and maintains tolerance to self-antigens. Recent studies have reported that defect in the CTLA-4 gene expression could affect its function and be involved in the development of various pathologies as autoimmune diseases and the outcome after Allogenic hematopoietic stem cell transplantation; indeed, the objective of our study is the search for the association of the CTLA-4 polymorphism with the susceptibility to red blood cells alloimmunizations. In this study we looked for the polymorphism of the CTLA-4 gene at the -318 C/T position in 35 β-thalassemic patients (15alloimmunized and 20 non alloimunized) followed at the children's hospital in Casablanca, and 20 healthy controls, by PCR-RFLP and Sanger sequencing. In our cohort, none of the group cases revealed the mutation carried out by PCR RFLP. Indeed, this result was confirmed by Sanger sequencing. This study does not find an association of -318C/T SNPs in CTLA-4 gene and RBC alloimmunization among our cohort. Following these preliminary results, an investigation of the other exons of the CTLA-4 gene on a large cohort is necessary to complete this study.



References

D. Langhi, E. M. A. Ubiali, J. F. C. Marques, M. de A. Verissimo, S. R. Loggetto, A. Silvinato and W. M. Bernardo, "Guidelines on Beta-thalassemia major – regular blood transfusion therapy: Associação Brasileira de Hematologia," Rev Bras Hematol E Hemoter 2016;38:341–5. https://doi.org/10.1016/j.bjhh.2016.09.003.

M. D. Cappellini, J. B. Porter, V. Viprakasit and A. T. Taher, "A paradigm shift on beta-thalassaemia treatment: How will we manage this old disease with new therapies?" Blood Rev 2018;32:300–11. https://doi.org/10.1016/j.blre.2018.02.001.

S. El Kababi, M. Benajiba, B. El Khalfi, J. Hachim and A. Soukri, "Red blood cell alloimmunizations in beta-thalassemia patients in Casablanca/Morocco: Prevalence and risk factors," Transfus Clin Biol 2019. https://doi.org/10.1016/j.tracli.2019.06.004.

P. Elhence, A. Solanki and A. Verma, "Red Blood Cell Antibodies in Thalassemia Patients in Northern India: Risk Factors and Literature Review," Indian J Hematol Blood Transfus 2014;30:301–8. https://doi.org/10.1007/s12288-013-0311-y.

I. Ben Amor, N. Louati, H. Khemekhem, A. Dhieb, H. Rekik, M. Mdhaffar and J. Gargouri, "Immunisation anti-érythrocytaire dans les hémoglobinopathies: à propos de 84 cas," Transfus Clin Biol 2012;19:345–52. https://doi.org/10.1016/j.tracli.2012.06.006.

A. Matteocci and L. Pierelli, "Red blood cell alloimmunization in sickle cell disease and in thalassaemia: current status, future perspectives and potential role of molecular typing," Vox Sang 2014;106:197–208. https://doi.org/10.1111/vox.12086.

E. Chevet "Thérapeutiques dans la β-Thalassémie," 2015.

E. Angelucci, S. Matthes-Martin, D. Baronciani, F. Bernaudin, S. Bonanomi, M. D. Cappellini and C. Peters, "Hematopoietic stem cell transplantation in thalassemia major and sickle cell disease: indications and management recommendations from an international expert panel," Haematologica 2014;99:811–20. https://doi.org/10.3324/haematol.2013.099747.

S. Achargui, A. Zidouh, S. Abirou, F. Z. Merhfour, S. Monsif, Amahrouch S and M. Benajiba, "Identification des allo-anticorps seuls et associés : bilan de trois années au centre régional de transfusion sanguine de Rabat/Maroc et difficultés de prise en charge transfusionnelle," Transfus Clin Biol 2017; 24:422–30. https://doi.org/10.1016/j.tracli.2017.04.006.

N. H. Smith, E. A. Hod, S. L. Spitalnik, J. C. Zimring and J. E. Hendrickson, "Transfusion in the absence of inflammation induces antigen-specific tolerance to murine RBCs," Blood 2012;119:1566–9. https://doi.org/10.1182/blood-2011-09-382655.

S. Sakaguchi, T. Yamaguchi, T. Nomura and M. Ono. "Regulatory T cells and immune tolerance," Cell 2008;133:775–87. https://doi.org/10.1016/j.cell.2008.05.009.

S. Read, V. Malmström and F. Powrie, "Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation," J Exp Med 2000;192:295–302. https://doi.org/10.1084/jem.192.2.295.

F. Eliana, P. Suwondo, A. Asmarinah, A. Harahap, S. Djauzi, J. Prihartono, T. G. D. Pemayun, "The Role of Cytotoxic T-lymphocyte-associated Protein 4 (CTLA-4) Gene, Thyroid Stimulating Hormone Receptor (TSHR) Gene and Regulatory T-cells as Risk Factors for Relapse in Patients with Graves Disease," Acta Medica Indones 2017;49:195–204.

R. Elshazli, A. Settin and A. Salama, "Cytotoxic T lymphocyte associated antigen-4 (CTLA-4) +49 A>G gene polymorphism in Egyptian cases with rheumatoid arthritis," Gene 2015;558:103–7. https://doi.org/10.1016/j.gene.2014.12.046.

J. Hammrich, S. Wittig, T. Ernst and B. Gruhn, "CTLA-4 polymorphisms: influence on transplant-related mortality and survival in children undergoing allogeneic hematopoietic stem cell transplantation," J Cancer Res Clin Oncol 2018;144:587–92. https://doi.org/10.1007/s00432-018-2578-8.

T. L. Walunas, D. J. Lenschow, C. Y. Bakker, P. S. Linsley, G. J. Freeman, J. M. Green and J. A. Bluestone, "CTLA-4 can function as a negative regulator of T cell activation," Immunity 1994;1:405–13. https://doi.org/10.1016/1074-7613(94)90071-x.

E. Valk, C. E. Rudd and H. Schneider, "CTLA-4 trafficking and surface expression," Trends Immunol 2008;29:272–9. https://doi.org/10.1016/j.it.2008.02.011.

A. Ligers, N. Teleshova, T. Masterman, W-X Huang, and J. Hillert, "CTLA-4 gene expression is influenced by promoter and exon 1 polymorphisms," Genes Immun 2001;2:145–52. https://doi.org/10.1038/sj.gene.6363752.

S. Orrù, N. Orrù, E. Manolakos, R. Littera, G. Caocci, G. Giorgiani, and G. La Nasa, "Recipient CTLA-4*CT60-AA genotype is a prognostic factor for acute graft-versus-host disease in hematopoietic stem cell transplantation for thalassemia," Hum Immunol 2012;73:282–6. https://doi.org/10.1016/j.humimm.2011.12.014.

V. B. Oliveira, M. R. Dezan, F. C. A. Gomes, S. F. Menosi Gualandro, J. E. Krieger, A. C. Pereira, et al. -318C/T polymorphism of the CTLA-4 gene is an independent risk factor for RBC alloimmunization among sickle cell disease patients. Int J Immunogenet 2017; 44:219–24. https://doi.org/10.1111/iji.12334.

M. Narooie-Nejad, O. Taji, D. M. Kordi Tamandani, M. A. Kaykhaei, "Association of CTLA-4 gene polymorphisms −318C/T and +49A/G and Hashimoto’s thyroidits in Zahedan, Iran." Biomed Rep 2017;6:108–12. https://doi.org/10.3892/br.2016.813.

A. Pérez-García, R. De la Cámara, J. Román-Gómez, A. Jiménez-Velasco, M. Encuentra, J. B. Nieto JB and GVHD/Immunotherapy Committee of the Spanish Group of Hematopoietic Stem Cell Transplantation, "CTLA-4 polymorphisms and clinical outcome after allogeneic stem cell transplantation from HLA-identical sibling donors," Blood 2007;110:461–7. https://doi.org/10.1182/blood-2007-01-069781.

M. K. Misra, A. Mishra, S. R. Phadke, and S. Agrawal, "Association of functional genetic variants of CTLA4 with reduced serum CTLA4 protein levels and increased risk of idiopathic recurrent miscarriages," Fertil Steril 2016;106:1115-1123.e6. https://doi.org/10.1016/j.fertnstert.2016.06.011.

A. B. Ryder, J. E. Hendrickson and C. A. Tormey, "Chronic inflammatory autoimmune disorders are a risk factor for red blood cell alloimmunization," Br J Haematol 2016;174:483–5. https://doi.org/10.1111/bjh.13781.

Downloads

Download data is not yet available.

##plugins.themes.bootstrap3.article.details##

How to Cite
El Kababi, S., El Khalfi, B., El Maani, K. ., & Soukri, A. (2021). Analysis of CTLA-4 -318C/T Polymorphism in Thalassemia Patients Transfused at the Casablanca Children’s Hospital (Morocco). European Journal of Medical and Health Sciences, 3(5), 39–42. https://doi.org/10.24018/ejmed.2021.3.5.1054